Mepsevii Drug Information

The clinical program for MEPSEVII included 23 patients with MPS VII, 17 of whom were evaluable for efficacy, 20 for safety, and 23 for immunogenicity. Patients were enrolled in clinical trials and expanded access protocols receiving treatment at doses up to 4 mg/kg once every two weeks for up to 187 weeks. The patients ranged in age from 5 months to 25 years.

Sixteen patients were younger than 18 years of age. Studies 301 and 202 Study UX003-CL301 (referred to as Study 301, NCT02230566) was a randomized start trial of MEPSEVII 4 mg/kg every two weeks in patients with MPS VII. Twelve patients were randomized to one of four placebo durations before crossing over to active treatment. Three patients received MEPSEVII immediately for a duration of 48 weeks, 3 patients received placebo for 8 weeks then MEPSEVII for 40 weeks, 3 patients received placebo for 16 weeks then MEPSEVII for 32 weeks, and 3 patients received placebo for 24 weeks then MEPSEVII for 24 weeks.

Of the 12 patients enrolled in the trial, 4 were male and 8 were female and ranged in age from 8 to 25 years (median 14 years). Nine patients were younger than 18 years of age. The majority of the patients were white (75%), with 50% of Hispanic or Latino ethnicity. Patients who were enrolled in Study 301 were eligible to roll over to Study UX003-CL202 (referred to as Study 202, NCT02432144), an open-label extension trial in which patients received additional doses of MEPSEVII at 4 mg/kg intravenously every other week for up to 144 weeks.

Ten patients rolled over directly from the end of Study to Week 0 of Study 202, while 2 patients (17%) had treatment gaps before enrolling in Study 202. In Study 301, motor function, forced vital capacity, and visual acuity were assessed after 24 weeks of MEPSEVII treatment and measured against pre-specified minimal important differences. The extremely small population of patients with MPS VII globally necessitated the enrollment of all patients able to participate resulting in a highly heterogeneous group. Clinical endpoints were not assessable in some patients due to their extent of disease, age or level of cognition.

Repeated assessments of the six minute walk test (6MWT) were feasible in ten of 12 patients and are described further below. Of the three patients who improved on their 6MWT (Figure 1, left panel), two also were noted to have improvement in balance and gross motor proficiency as assessed by the Bruininks-Oseretsky Test of Motor Proficiency (BOT-2). In this trial, the mean difference in 6MWT distance between MEPSEVII and placebo treatment periods in patients able to perform the test at baseline and subsequent visits through Week 24 is shown in Table 3. The mean difference in 6MWT distance increases with increased treatment duration, however, due to the small size of the trial, standard errors are large. Table 3. Mean Difference in 6MWT Distance (meters) Between MEPSEVII and Placebo Treatment (Study 301) in Patients with MPS VII Duration of MEPSEVII Treatment LS mean 6MW T (m eters ) ( ± S tandard Error )* Number and Treatment Assignment of Patients Included in Analyis ** 8 weeks -11 (± 24) 5 placebo period; 8 MEPSEVII period 16 weeks 13 (± 32) 5 placebo period; 8 MEPSEVII period 24 weeks 18 (± 33) 5 placebo period; 8 MEPSEVII period *ANCOVA analysis of change from baseline in least squares (LS) mean between placebo and MEPSEVII for different periods, after adjusting for study cohort, age, and baseline 6MWT distance.

Patients who used assistive devices were imputed as zeros in the analysis. **Number and treatment assignment of patients included in the analysis was based upon a randomized start trial design and patient ability to complete testing. Due to no placebo period for the three patients who received 48 weeks of MEPSEVII in the first cohort of the randomized start design, more data were available for analyses during the treatment period (n=8) than during the placebo period (n=5). While data from 8 participants were available at each time point, due to missing observations, the 8 participants were not the same across all time points. The observed individual 6MWT distances for the 10 patients who could perform the test in Study 301 and Study 202 through Week 184 are presented in Figure 1. The course of three patients with improvement in distance walked of at least 60 meters during the 301 Study compared to the start of MEPSEVII treatment (Week 0) is shown in the left panel; the relatively stable course in the remaining seven patients, including those who used assistive devices, is shown in the right panel.

Figure 1. 6MWT Distance for MPS VII Patient s in Studies 301 and 202 Patient 10 did not use an assistive device at baseline but started using an assistive device post-baseline from Treatment Week 8. Patients 6 and 9 consistently used an assistive device at all visits. A solid line indicates the unassisted assessments and a dotted line indicates the assisted assessments. Liver and Spleen Volume In Study 301, imaging by MRI or ultrasound to assess liver and spleen volume was performed in seven of the 12 patients.

Most liver volumes were normal or below normal size at baseline (mean 1,591 mL, range 742 to 2,207 mL), and on average were unchanged after treatment (mean 1,459 mL, range 876 to 1,851 mL). Spleen volumes generally were normal or below normal size at baseline (mean 325 mL, range 131 to 491 mL) and on average were unchanged after treatment (mean 360 mL, range 200 to 582 mL). Study 203 UX003-CL203 (referred to as Study 203; NCT 02418455 ) was an open-label, uncontrolled single arm study that enrolled 8 patients less than 5 years of age who received MEPSEVII at a dose of 4 mg/kg every two weeks for 48 weeks of treatment and up to an additional 240 weeks during an optional continuation period. The study evaluated urinary GAG excretion, growth and hepatosplenomegaly. With long-term treatment, urinary GAG levels remained decreased upon exposure to MEPSEVII. At baseline, all 8 patients had impaired growth, and height remained near the 5th percentile relative to age-matched gender norms throughout the trial.

No significant changes in hepatosplenomegaly were observed. Other Investigations Study UX003-CL201 (referred to as Study 201, NCT01856218) was a single arm, open-label, dose exploration trial completed outside the United States that enrolled three MPS VII patients, ranging in age from 5 years to 25 years. Two patients were male; two patients were white and one was Asian.

After 120 weeks of exposure to MEPSEVII, one patient demonstrated a 21% improvement over baseline in forced vital capacity (FVC% predicted) on pulmonary function testing in addition to a 105 meter improvement in the 6MWT. Two other patients with baseline hepatosplenomegaly had reduction in liver volume (24% and 53%) and spleen volume (28% and 47%) after 36 weeks of MEPSEVII treatment. Expanded access to MEPSEVII treatment was provided to a pediatric patient with MPS VII who required continuous ventilatory support at the start of treatment and was subsequently able to tolerate 9 hours daily off ventilator support after 164 weeks of MEPSEVII treatment. Figure 1